Forecast for Vaccine Stocks After Coronavirus Pandemic Passes
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
More Videos
The GLP-1 Effect: How Weight-Loss Drugs Are Changing the Business of Healthcare
America's GLP-1 boom is reshaping healthcare. SHARx co-founder Paul Pruitt explains who pays, why costs are surging, and what comes next.
Experian's AI Strategy Is Reshaping Financial Services
From Money 20/20, Experian UK & Ireland CEO Malin Holmberg discusses the trends, opportunities and innovations shaping fintech's future.
How The Brooklyn Army Terminal Became NYC's $100 Million Climate Hub
NYC just invested $100 million to turn a historic military base into a climate tech proving ground. We went inside the Brooklyn Army Terminal to find out why.
Why AI Companies May Soon Be Sharing Their Most Powerful Models With the Government
Politico's Cheyenne Haslett breaks down Trump's new AI executive order, the AI race with China, industry reaction, and what's next for regulation.
Inside the Aerospace IPO Positioning for the Next Decade of Defense Growth
Applied Aerospace & Defense CEO Trip Ferguson discusses the company's IPO, defense spending, space innovation, and the future of U.S. aerospace manufacturing.
How Crunch Fitness Is Redefining Your Exercise Routine
Jim Rowley, CEO of Crunch Fitness, discusses affordable fitness, industry growth, and why value-focused gyms continue to attract members.
